Anne Zaremba

1.9k total citations
28 papers, 317 citations indexed

About

Anne Zaremba is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Anne Zaremba has authored 28 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 12 papers in Molecular Biology and 12 papers in Immunology. Recurrent topics in Anne Zaremba's work include Immunotherapy and Immune Responses (12 papers), Melanoma and MAPK Pathways (11 papers) and Cutaneous Melanoma Detection and Management (9 papers). Anne Zaremba is often cited by papers focused on Immunotherapy and Immune Responses (12 papers), Melanoma and MAPK Pathways (11 papers) and Cutaneous Melanoma Detection and Management (9 papers). Anne Zaremba collaborates with scholars based in Germany, United States and United Kingdom. Anne Zaremba's co-authors include Dirk Schadendorf, Elisabeth Livingstone, Lisa Zimmer, Selma Ugurel, Oliver Schanz, Marc Beyer, Christoph Garbers, Percy A. Knolle, Christian Kurts and Joachim L. Schultze and has published in prestigious journals such as PLoS ONE, Clinical Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Anne Zaremba

25 papers receiving 315 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anne Zaremba Germany 10 201 113 107 45 24 28 317
Jason Cham United States 8 272 1.4× 61 0.5× 173 1.6× 84 1.9× 16 0.7× 20 355
Lisa Boselli France 10 281 1.4× 72 0.6× 154 1.4× 83 1.8× 55 2.3× 13 383
David Sermer United States 10 219 1.1× 112 1.0× 93 0.9× 17 0.4× 14 0.6× 22 387
Niels J. Brouwer Netherlands 15 265 1.3× 100 0.9× 141 1.3× 64 1.4× 43 1.8× 27 494
Simona Pigozzi Italy 9 121 0.6× 101 0.9× 61 0.6× 51 1.1× 34 1.4× 24 320
Candy Garcia United States 3 393 2.0× 81 0.7× 207 1.9× 101 2.2× 23 1.0× 3 484
Grégoire Berthod Switzerland 10 298 1.5× 119 1.1× 123 1.1× 95 2.1× 19 0.8× 24 433
Danni Yu United States 12 242 1.2× 127 1.1× 177 1.7× 62 1.4× 17 0.7× 20 419
Ming Gu China 7 250 1.2× 84 0.7× 206 1.9× 46 1.0× 20 0.8× 12 381
J J Oudejans Netherlands 8 239 1.2× 57 0.5× 121 1.1× 12 0.3× 26 1.1× 12 364

Countries citing papers authored by Anne Zaremba

Since Specialization
Citations

This map shows the geographic impact of Anne Zaremba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Zaremba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Zaremba more than expected).

Fields of papers citing papers by Anne Zaremba

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Zaremba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Zaremba. The network helps show where Anne Zaremba may publish in the future.

Co-authorship network of co-authors of Anne Zaremba

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Zaremba. A scholar is included among the top collaborators of Anne Zaremba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Zaremba. Anne Zaremba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zaremba, Anne, Antje Sucker, Gennadiy Zelinskyy, et al.. (2023). HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance. Clinical Cancer Research. 29(15). 2894–2907. 9 indexed citations
3.
Tarantino, Giuseppe, Anne Zaremba, Tuulia Vallius, et al.. (2023). 1166P Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary melanoma to in-transit and distant metastasis. Annals of Oncology. 34. S694–S694. 1 indexed citations
4.
Meister, Jaroslawna, Mathias Stiller, Sven-Holger Puppel, et al.. (2023). TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entities. PLoS ONE. 18(7). e0281487–e0281487. 2 indexed citations
5.
Hegedüs, Luca, Elisabeth Livingstone, Ágnes Bánkfalvi, et al.. (2022). The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition. International Journal of Molecular Sciences. 23(6). 3324–3324. 7 indexed citations
6.
Ferdinandus, Justin, Anne Zaremba, Lisa Zimmer, et al.. (2022). Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma. Cancer Imaging. 22(1). 11–11. 6 indexed citations
7.
Zaremba, Anne, Friedegund Meier, Christian Schlein, et al.. (2022). Clinical and pathological characteristics of familial melanoma with germline TERT promoter variants. Pigment Cell & Melanoma Research. 35(6). 573–586. 1 indexed citations
8.
Zaremba, Anne, Alexander M.M. Eggermont, Caroline Robert, et al.. (2021). The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. European Journal of Cancer. 155. 268–280. 45 indexed citations
9.
Dimitriou, Florentia, Anne Zaremba, Clara Allayous, et al.. (2021). Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. European Journal of Cancer. 149. 37–48. 17 indexed citations
10.
Chorti, Eleftheria, Sied Kebir, Kathy Keyvani, et al.. (2021). Leptomeningeal disease from melanoma—Poor prognosis despite new therapeutic modalities. European Journal of Cancer. 148. 395–404. 21 indexed citations
11.
Jansen, Philipp, Hansgeorg Müller, Georg Lodde, et al.. (2021). GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors. Frontiers in Genetics. 12. 663272–663272. 17 indexed citations
12.
Bhave, Prachi, Tasnia Ahmed, Alexander N. Shoushtari, et al.. (2021). 1047P Efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM). Annals of Oncology. 32. S876–S877. 3 indexed citations
13.
Zaremba, Anne, Lisa Zimmer, Klaus Griewank, et al.. (2020). Immuntherapie beim malignen Melanom. Der Internist. 61(7). 669–675. 12 indexed citations
14.
Jockenhöfer, Finja, et al.. (2019). Pruritus in patients with chronic leg ulcers: A frequent and often neglected problem. International Wound Journal. 16(6). 1464–1470. 4 indexed citations
15.
Jansen, Philipp, Ioana Cosgarea, Rajmohan Murali, et al.. (2019). Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi. Cancers. 11(4). 546–546. 8 indexed citations
16.
Zaremba, Anne, Rajmohan Murali, Philipp Jansen, et al.. (2019). Clinical and genetic analysis of melanomas arising in acral sites. European Journal of Cancer. 119. 66–76. 24 indexed citations
17.
Zaremba, Anne, et al.. (2019). Arteriovenous fistula of superficial temporal vessels. Folia Morphologica. 78(4). 879–882. 3 indexed citations
18.
Cosgarea, Ioana, Anne Zaremba, & Uwe Hillen. (2019). Extramammärer Morbus Paget. Der Hautarzt. 70(9). 670–676.
19.
Zaremba, Anne, Eleftheria Chorti, Finja Jockenhöfer, et al.. (2019). Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?. Journal for ImmunoTherapy of Cancer. 7(1). 141–141. 10 indexed citations
20.
Zaremba, Anne, et al.. (1975). [Selection of bases for antibiotic-containing suppositories. III. Study of biological availability of antibiotics in some suppository bases].. PubMed. 32(1). 89–93. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jason Cham Breakdown of academic impact, for papers by Lisa Boselli Breakdown of academic impact, for papers by David Sermer Breakdown of academic impact, for papers by Niels J. Brouwer Breakdown of academic impact, for papers by Simona Pigozzi Breakdown of academic impact, for papers by Candy Garcia Breakdown of academic impact, for papers by Grégoire Berthod Breakdown of academic impact, for papers by Danni Yu Breakdown of academic impact, for papers by Ming Gu Breakdown of academic impact, for papers by J J Oudejans
Rankless by CCL
2026